Analysis of Novavax share price

We would notably recommend you follow information concerning the growth and aging of the global population which will exert a direct influence on Novavax sales.

Of course, it is also important to monitor closely and regularly the different tests and trials undertaken by Novavax for the preparation of new vaccines as well as the success or failure of different phases in clinical trials. This information will often initiate strong reactions on the stock markets.

In the same way it is recommended to pay particular attention to the development of new products that obtain the health authorities approval for launching onto the market.

Changes in regulations relating to pharmaceutical products will also exert a direct influence on the activities of the Novavax Company and you should therefore monitor all significant changes in the countries where Novavax operates.

In the same way we would also follow the implementation of strategic partnerships by Novavax particularly with certain large laboratories. It is in fact these partnerships that have enabled this major biotech company to finance its research and thereby generate its income.

BioNTech

This German company, specialised in biotechnology, is of course a direct competitor of Novavax. It is specialised in the development and production of active immunotherapies for the treatment of severe illnesses. The solutions developed by this group are based on the RNA messenger and notably concern immunotherapy against cancer, vaccines against infectious diseases and protein replacement therapies for rare diseases as well as cellular therapy, new antibodies and small molecule immunomodulators such as for optional cancer treatments. BioNTech has also perfected a human therapy based on mRNA for intravenous administration with the aim of introducing mRNA based individualised cancer immunotherapy for clinical testing and has developed its own manufacturing procedure.

Pfizer 

Another direct competitor of the Novavax Group is none other than the American giant Pfizer which was created in 1849 and is currently present in over 150 countries worldwide. This company is the world leader in this activity sector in terms of turnover and stock market capital. The success of this group is primarily due to its merger operations with other companies, which are often its competitors such as Pharmacia, Warber Lambert and Wyeth.

Astrazeneca 

Another direct competitor to Novavax is the Astrazeneca pharmaceutical group. This is an Anglo-Swedish group created through the merger in 1999 of the Astra and Zeneca companies. Nowadays the Astrazeneca group employs over 63,000 people around the world in various sectors including research, development, manufacturing and sales of pharmaceutical products and a provider of services for medical care. Among the sectors that Astrazeneca is specialised in we note diabetes, anaesthesiology, cardiology, infectiology, gastroenterology, oncology, neurology and pneumology.

Moderna Therapeutics

Finally, the last current major competitor to the Novavax Group is undoubtedly the American group Moderna Therapeutics which is also a biotechnology company specialised in the development of protein therapies based on the RNA messenger technology. The technology which has proved a success for this company also uses an mRNA composed of nucleotide analogues with the objective of initiating the body’s natural processes including the production of proteins in human cells.

AGC Biologics

In 2020 the Novavax Company implemented a strategic partnership with the global pharmaceutical company AGC Biologics. This company is specialised in development through sub-contracts and announced the extension of an already existing partnership with this American biotech company which again is specialised in the creation of next generation vaccines for serious infectious diseases. In this manner AGC Biologics can prepare for the production of Matrix-M, the adjuvant component of Novavax, for the development of a vaccine against the Covid-19 coronavirus in its installation based in Copenhagen. Thereby AGC Biologics can extend its offer of the Matrix-M adjuvant for the vaccine to its Seattle installation with the aim of enabling Novavax to supply the American territory. The vaccine concerned here is a stable pre-fusion protein which is produced through its patented nanoparticle technology. Through this partnership AGC Biologics can optimise the development of procedures for the increased production of Matrix-M and enable Novavax to provide a significant supply throughout the world in 2020 and 2021.

Takeda Pharmaceutical

Still in 2020, Novavax implemented a strategic partnership agreement with the Japanese company Takeda Pharmaceutical. The two companies actually formed this alliance with the aim of developing, manufacturing and selling NVX-CoV2373, a vaccine candidate against Covid-19. In this way Takeda could benefit from financial support from the Japanese government ministry of health, work and wellbeing which agreed to assist with technological transfer costs, as well as the implementation of infrastructures and manufacturing. Over 250 million doses have been projected for annual production. The vaccine concerned is a stable pre-fusion protein manufactured using recombined protein nanoparticle technology including the exclusive Novavax Matrix-M adjuvant. It is therefore mainly in the clinical development and production that the two companies will collaborate. Novavax will thereby transfer their manufacturing technology for the production of the vaccine antigen as well as the Matrix-M adjuvant and Takeda will manufacture and distribute the vaccine in Japan.